Dr. Li joined BVCF as a Partner in 2007. He has over 20 years of China and U.S. life sciences expertise in private equity and corporate investment, as well as entrepreneurship, operational management, and scientific discovery. Prior to joining BVCF, he was responsible for H&Q Asia Pacific's life sciences investment and management in the Asia Pacific region (through its vehicle, Sinogen.) Before that, he served as a founding scientist of Human Genome Sciences, a human genomics pioneering company later on acquired by GSK for $3 billion. Dr. Li was appointed as an overseas member of the China National Committee for New Drug Development in 1996. He served on the board of the Sino-American Pharmaceutical Association (SAPA). Dr. Li holds numerous patents and earned his PhD in Molecular Biology and Bio-chemistry at Harvard University, as a fellow of CUSBEA's fourth class.